Entinostat (MS-275): Advancing Precision Epigenetic Modulation in Cancer and Regenerative Research

Principle Overview: Selective HDAC1/3 Inhibition and Mechanistic Impact

Entinostat (MS-275, SNDX-275) is a potent, orally bioavailable inhibitor targeting class I histone deacetylases (HDACs), with high selectivity for HDAC1 (IC₅₀: 0.368 μM) and HDAC3 (IC₅₀: 0.501 μM), and minimal activity on HDAC8 (IC₅₀: 63.4 μM) (product_spec). By blocking HDAC activity, Entinostat increases histone acetylation, resulting in chromatin relaxation and transcriptional reprogramming. This epigenetic modulation underpins its ability to inhibit cancer cell proliferation and induce apoptosis in diverse models, including breast, colon, lung, myeloma, ovarian, pancreatic, prostate, and leukemia cells (entinostat.net).

Step-by-Step Workflow: Optimizing Entinostat Applications

Integrating Entinostat into experimental workflows demands careful attention to solubility, dosing, and biological context. Below, we outline a robust, literature-driven protocol for both in vitro and in vivo studies:

• Compound Preparation: Dissolve Entinostat in DMSO to create a 10 mM stock solution (solubility ≥18.8 mg/mL in DMSO) (product_spec). Store aliquots at <-20°C and use within one month to avoid degradation (workflow_recommendation).
• Cellular Assays: Treat cancer cell lines with 0.1–2 μM Entinostat for 24–72 hours. This range robustly inhibits HDAC1/3, suppresses proliferation, and induces apoptosis in most solid tumor models (entinostat.net).
• In Vivo Studies: For murine cancer models, administer Entinostat orally at 5–10 mg/kg, 2–3 times per week. This regimen produces significant tumor growth inhibition and quantifiable increases in acetyl-histone markers (product_spec).
• Regenerative Biology: In axolotl limb regeneration, local injection of Entinostat at 5 μM into the amputation site delays blastema formation, providing a functional readout of HDAC1-dependent regeneration (paper).

Protocol Parameters

• HDAC inhibition in cancer cells | 0.5 μM Entinostat, 48 h incubation | breast, colon, and lung cancer cell lines | Maximizes apoptosis and proliferation block while minimizing cytotoxicity | entinostat.net
• In vivo solid tumor suppression | 7.5 mg/kg oral, 3x/week | mouse xenograft models | Achieves sustained HDAC1/3 inhibition and tumor regression | product_spec
• Axolotl limb regeneration assay | 5 μM local injection, single dose post-amputation | amphibian regeneration research | Directly tests HDAC1-dependent tissue regrowth | paper

Key Innovation from the Reference Study

The landmark study by Wang et al. (paper) established that nerve-mediated HDAC1 upregulation is essential for axolotl limb regeneration. They demonstrated a biphasic surge in HDAC1 expression during blastema formation, and showed that local administration of Entinostat (MS-275) robustly inhibited HDAC activity and delayed limb regrowth without compromising wound healing. This model provides a powerful platform for dissecting the role of epigenetic regulation in regeneration and highlights Entinostat as a precise tool for modulating tissue-specific HDAC1 activity. For practical workflows, these insights translate into using Entinostat not just in oncology, but also in developmental and regenerative biology assays where HDAC1 function is under investigation.

Advanced Applications and Comparative Advantages

Entinostat’s high selectivity for HDAC1/3 distinguishes it from pan-HDAC inhibitors, enabling focused studies on class I HDACs with reduced off-target effects (romidepsin.org). For cancer research, this selectivity supports clearer mechanistic insights into cancer cell proliferation inhibition and apoptosis induction in cancer cells. In clinical translation, phase I studies have established its tolerability and recommended dosing regimens for combination strategies in advanced solid tumor clinical trials (product_spec).

In the context of retinoblastoma treatment research, Entinostat has demonstrated the ability to reduce tumor burden and increase histone acetylation in retinal tissues, providing a bridge from in vitro insight to in vivo efficacy. Furthermore, protocols derived from axolotl studies now enable regenerative biologists to manipulate HDAC1 activity with temporal and spatial precision, which was previously unattainable.

Comparatively, the guide at entinostat.net details how Entinostat enables reproducible epigenetic modulation versus broader-spectrum HDAC inhibitors. These resources complement each other: the referenced paper grounds the mechanistic rationale for HDAC1 targeting in regeneration, while the comparative workflow guides expand on optimization and troubleshooting in cancer models.

Troubleshooting and Optimization Tips

• Solubility Challenges: Entinostat is insoluble in water but dissolves efficiently in DMSO (≥18.8 mg/mL) and with ultrasonic treatment in ethanol (≥7.4 mg/mL). Always prepare stock solutions in DMSO for consistency (product_spec).
• Compound Degradation: Avoid repeated freeze-thaw cycles and store aliquots at <-20°C. Use freshly thawed stocks within one month to ensure activity (workflow_recommendation).
• Dose-Response Optimization: For new cell lines or tissues, conduct a pilot range-finding assay (0.05–2 μM) to calibrate HDAC inhibition versus cytotoxicity (entinostat.net).
• In Vivo Dosing: Monitor body weight and general health in animal models to detect off-target toxicity, particularly at higher doses or in combination studies (workflow_recommendation).
• Assay Readouts: Confirm HDAC inhibition by assessing acetyl-histone H3/H4 levels via western blot or immunofluorescence, and pair with cell viability/apoptosis assays for comprehensive results (romidepsin.org).

For comprehensive troubleshooting strategies, researchers can refer to the protocol-focused comparison at 5alphareductaseinhibitor.com, which details actionable steps for maximizing reproducibility with APExBIO’s Entinostat.

Integration with Existing Literature and Product Ecosystem

Entinostat (MS-275, SNDX-275), provided by APExBIO, stands out for its stringent quality controls and published performance in both cancer and regenerative models. As outlined in the review at naloxonebuy.com, strategic experimental design leveraging Entinostat’s selectivity can uncover both mechanistic and translational opportunities. The referenced axolotl study extends the utility of Entinostat beyond oncology, bridging epigenetic modulation in cancer with regenerative medicine—a novel and rapidly maturing cross-domain application.

Future Outlook

Building on robust evidence for Entinostat’s efficacy in cancer cell proliferation inhibition and apoptosis induction in cancer cells (entinostat.net), the translational trajectory now includes precision manipulation of HDAC1 in tissue regeneration. As more studies harness both in vitro and in vivo applications, the convergence of oncology and regenerative biology will offer new therapeutic avenues and biomarker strategies. However, limitations include the need for tissue-specific dosing, potential off-target effects at higher concentrations, and the requirement for further clinical validation in regenerative models. Researchers are encouraged to leverage the expanding workflow resources and adapt protocols to emerging biological contexts, always grounding innovations in published evidence and rigorously controlled experimentation.

To source Entinostat (MS-275, SNDX-275) for your next set of epigenetic research experiments, visit the product page at APExBIO.